OPPM
RUBY

Opus Point Partners Management’s Rubius Therapeutics, Inc RUBY Stock Holding History

Opus Point Partners Management’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-21,610
Closed -$391K – 76
2019
Q1 		$391K Buy
+21,610
New +$332K 0.53% 47

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Opus Point Partners Management's RUBY Position: Q2 2019 in Review

Opus Point Partners Management sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2019, closing a stake of 21,610 shares — an estimated $391K sold.

Opus Point Partners Management first reported a position in RUBY in Q1 2019 and held it in 1 quarter. The position peaked at $391K in Q1 2019. 69 funds tracked by Wall St. Rank hold RUBY as of Q2 2019.

  • Opus Point Partners Management reported no remaining Rubius Therapeutics, Inc position as of Q2 2019 after selling out during the quarter.
  • Opus Point Partners Management sold 21,610 Rubius Therapeutics, Inc shares in Q2 2019, an estimated $391K.
  • Opus Point Partners Management first reported a position in Rubius Therapeutics, Inc in Q1 2019 and held it in 1 quarter.
  • Opus Point Partners Management's Rubius Therapeutics, Inc position peaked at $391K in Q1 2019.
  • 69 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2019.

Based on Opus Point Partners Management's 13F filing for Q2 2019, filed 14 Aug 2019.